IAVI Report

After four decades of HIV research, the field seeks to make progress against one of the most difficult pathogens vaccine researchers have ever faced.

A timeline of major milestones in the decades-long effort to develop an HIV vaccine.

In conversation with IAVI founder Seth Berkley and CEO Mark Feinberg

This year IAVI is celebrating its 25th anniversary. And so are we. The first issue of IAVI Report was published in the summer of 1996. It described IAVI’s formation and mission, offered the scientific reasons for why an AIDS vaccine was feasible, chronicled advances in AIDS vaccine research, included the voice of one of Uganda’s…

In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.

John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.

Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.

The last time I penned a letter in this publication, nearly a year ago, I closed by saying: “If science is our best hope, we are in good hands.” That certainly proved to be the case. There are now three authorized COVID-19 vaccines in the U.S., and seven that have received an Emergency Use Listing…

How will the results from recent trials set the course for future research?

SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?

An interview with Seth Berkley, chief executive officer of Gavi, the Vaccine Alliance

Numerous monoclonal antibodies are already in development for both treatment and prevention. There are many unanswered questions, but, if they work, antibodies may play a role in ending this pandemic and in responding to future viral outbreaks.